TITLE

Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma

AUTHOR(S)
Worel, N.; Greinix, H.; Ackermann, J.; Kaufmann, H.; Urbauer, E.; Höcker, P.; Gisslinger, H.; Lechner, K.; Kalhs, P.; Drach, J.
PUB. DATE
June 2001
SOURCE
Annals of Hematology;Jun2001, Vol. 80 Issue 6, p345
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Interphase cytogenetic analysis of chromosome 13q14 was performed in 28 patients with multiple myeloma (MM) receiving high-dose therapy followed by autologous (n=24) or allogeneic (n=4) stem cell support. Eleven (39%) patients were found to have a deletion of chromosome 13q14. Response rates to high-dose therapy were independent of the chromosome 13 status, but patients with a deletion of 13q14 had a significantly shorter progression-free (p=0.001) and overall survival (p=0.012) than patients with normal chromosome 13q14. Our results indicate that high-dose therapy appears promising in patients with normal chromosome 13, whereas in patients with a deletion of 13q14 innovative therapeutic concepts are warranted.
ACCESSION #
15684739

 

Related Articles

  • Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative. Gertz, Morie A.; Ansell, Stephen M.; Dingli, David; Dispenzieri, Angela; Buadi, Francis K.; Elliott, Michelle A.; Gastineau, Dennis A.; Hayman, Suzanne R.; Hogan, William J.; Inwards, David J.; Johnston, Patrick B.; Kumar, Shaji; Lacy, Martha Q.; Leung, Nelson; Micallef, Ivana N. M.; Porrata, Luis F.; Schafer, Barbara A.; Wolf, Robert C.; Litzow, Mark R. // Mayo Clinic Proceedings;Oct2008, Vol. 83 Issue 10, p1131 

    We report on the feasibility of outpatient transplant in 716 patients undergoing autologous stem cell transplant for multiple myeloma at Mayo Clinic's site in Rochester, MN, from January 1, 2000, through October 31, 2007. We also report on the development and effect of a multidisciplinary...

  • ‘Light-chain escape-multiple myeloma’—an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. Kühnemund, A.; Liebisch, P.; Bauchmüller, K.; zur Hausen, A.; Veelken, H.; Wäsch, R.; Engelhardt, M. // Journal of Cancer Research & Clinical Oncology;Mar2009, Vol. 135 Issue 3, p477 

    More intensive and novel therapy options in multiple myeloma (MM) hold the promise to improve treatment outcome. However, disease evolution, induced with long disease duration and extensive pretreatment, has resulted in changes in the biological behaviour of MM and unusual relapse emergence,...

  • Phase I–II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma. Weaver, C H; Zhen, B; Schwartzberg, L S; Leff, R; Magee, M; Geier, L; Deaton, K; Lewkow, L; Buckner, C D // Bone Marrow Transplantation;8/1/98, Vol. 22 Issue 3, p245 

    This study was designed to determine the maximum tolerated dose (MTD) of high-dose melphalan (HDM), with peripheral blood stem cell support, that could be given twice within 90 days to patients with multiple myeloma. Twenty patients received tandem HDM at 160, 180 or 200 mg/m2 and a total of 55...

  • Antigen-specificity of oligoclonal abnormal protein bands in multiple myeloma after allogeneic stem cell transplantation. Rahlff, Janina; Trusch, Maria; Haag, Friedrich; Bacher, Ulrike; Horst, Andrea; Schlüter, Hartmut; Binder, Mascha // Cancer Immunology, Immunotherapy;Oct2012, Vol. 61 Issue 10, p1639 

    Myeloma patients may develop oligoclonal immunoglobulins, so-called abnormal protein bands (APB), after stem cell transplantation. APB do not correspond to the patient's paraprotein and confer a good prognosis. We set out to investigate whether such APB represent a humoral anti-myeloma immune...

  • Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeic stem cell transplantation in mice. Zeis, M.; Frenzke, H.; Schmitz, N.; Uharek, L.; Steinmann, J. // Bone Marrow Transplantation;2/1/2002, Vol. 29 Issue 3, p213 

    Presents a study which examined the immunological effects of syngeneic peripheral blood stem cell transplantation given in conjunction with idiotype-loaded dendritic cell vaccination for multiple myeloma. Review of literature on dendritic cells; Materials and methods used; Results.

  • Therapeutic advancements in multiple myeloma. Gozzetti, Alessandro; Candi, Veronica; Papini, Giulia; Bocchia, Monica // Frontiers in Oncology;Sep2014, Vol. 4, p1 

    Multiplemyeloma survival has significantly improved in the latest years due to a broad spectrum of novel agents available for treatment. The introduction of thalidomide, bortezomib, and lenalidomide together with autologous stem-cell transplantation has considerably increased complete remission...

  • Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. Poenisch, Wolfram; Plötze, Madlen; Holzvogt, Bruno; Andrea, Marc; Schliwa, Thomas; Zehrfeld, Thomas; Hammerschmidt, Doreen; Schwarz, Maik; Edelmann, Thomas; Becker, Cornelia; Hoffmann, Franz; Schwarzer, Andreas; Kreibich, Ute; Gutsche, Kerstin; Reifenrath, Kolja; Schwarzbach, Heidrun; Heyn, Simone; Franke, Georg-Nikolaus; Jentzsch, Madlen; Leiblein, Sabine // Journal of Cancer Research & Clinical Oncology;Nov2015, Vol. 141 Issue 11, p2013 

    Introduction: Reliable information on stem cell toxicity and mobilization of stem cells for autologous stem cell transplantation (SCT) after induction treatment with a combination of bendamustine, prednisone and bortezomib (BPV) is missing. Materials and methods: A retrospective analysis of...

  • Cure of myeloma: hype or reality? Fassas, A; Shaughnessy, J; Barlogie, B // Bone Marrow Transplantation;Feb2005, Vol. 35 Issue 3, p215 

    Summary:High-dose treatment (HDT) with autologous stem cell transplant(s) (ASCT) improved survival, when compared to standard treatment, in multiple myeloma patients. Although the superiority of HDT is clearly recognized by the medical community, what is less appreciated is the disproportionate...

  • SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization. Gertz, M. A.; Gastineau, D. A.; Lacy, M. Q.; Dispenzieri, A.; Hayman, S. R.; Kumar, S. K.; Dingli, D.; Leung, N.; Wolf, R. C.; Hogan, W. J.; Buadi, F. K. // Bone Marrow Transplantation;Jul2011, Vol. 46 Issue 7, p956 

    SCT is important in the management of multiple myeloma. In the United States, the standard of care is administration of growth factors to accelerate neutrophil recovery after SCT. The need for growth factors after transplant has not been investigated recently. We analyzed a cohort of 166...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics